Projects: DDMoRe
Model based-drug development (MBDD) is a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD lies Modelling and Simulation (M&S), a technology providing the basis for informed, quantitative decision-making. M&S facilitates the continuous integration of available information related to a drug or disease into constantly-evolving mathematical models capable of describing and predicting the behavior of studied systems to address the questions researchers, regulators, and public health care bodies face when bringing drugs to patients.
The full adoption of MBDD is frustrated by the lack of common tools, languages and ontologies for M&S, which often leads to inefficient reuse of data and duplication of effort by academic, industrial and regulatory stakeholders. The Drug Disease Model Resources (DDMoRe) project aims at the development of a common definition language for data, models and workflows, along with an ontology based standard for storage and transfer of models and associated metadata.
My contribution
From July 2011 to March 2015, I worked on the "Interoperability framework" of the DDMoRe project. The interoperability framework houses a convertor toolbox for the conversion of modelling formats to ensure the seamless integration of existing and newly developed M&S tools.
Model Development Language and supporting tools
Model Development Language (MDL) is a domain-specific language for describing mathematical models used for kinetic drug analysis. It is composed of two parts, Model Coding Language (MCL), which specifies model parameters, and Task Execution Language (TEL), an R-based package to execute tasks associated with model specifications. The MCL comes with a specialized editing tool to assist drug analysts in creating MCL specifications.
